Sensus Healthcare, Inc.

Welcome to the Census Healthcare Fourth Quarter 2022 Earnings Conference Call. All participants will be in a listen-only mode today. And should you need any assistance during the call, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. To withdraw a question, please press star and then two. Please also note that this event is being recorded today. I would now like to turn the conference over to Kim Sutton-Goloduc with LHA Investor Relations. Please go ahead.

Thank you. This is Kim Goloduc with LHA. Thank you all for participating in today's call. Joining me from Census Healthcare are Joe Sardano, Chairman and Chief Executive Officer, Michael Sardano, President and General Counsel, and Javier Rampolla, Chief Financial Officer. As a reminder, some of the matters that will be discussed during today's call contain forward-looking statements within the meaning of federal securities law. All statements other than historical facts that address activities Census Healthcare assumes, plans, expects, believes, intends, or anticipates, and other similar expressions, will, should, or may occur in the future, are forward-looking statements. The forward-looking statements are management's beliefs based on currently available information as of the date of this conference call, February 9th, 2023. Census Healthcare undertakes no obligation to revise or update any forward-looking statements except as required by law. All forward-looking statements are subject to risks and uncertainties as described in the company's Forms 10-K and 10-Q. During today's conference call, references will be made to certain non-GAAP financial measures. Census believes these measures provide useful information for investors, yet they should not be considered as a substitute for GAAP, nor should they be viewed as a substitute for operating results determined in accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included in today's financial results press release. With that said, I'd like to turn the call over to Joe Sardano. Joe?

Thank you, Kim, and good afternoon, everyone. I address you today with the highest of confidence that Census Healthcare is better positioned today than ever before in our history with all the pieces in place for even greater execution of our business plan. We believe our superficial radiation therapy technology remains the number one choice for noninvasive treatment of skin cancer by both physicians and patients. Our improved reimbursement combined with our fair market value lease program provides our customers with an excellent patient acquisition tool, making the acquisition of our lead technology an easy transfer. Our new and improved high resolution ultrasound technology provides see and treat capability, which leads to great outcomes and patient reassurances. During the fourth quarter and throughout 2022, we strategically executed delivering strong revenue and profits. Importantly, we also took a number of steps to position Census for future success. These included assembling the staff and strategies to drive exceptional growth, building inventory, developing new aesthetic products that are anticipated to receive FDA clearance in the latter half of 2023, further investing in our Sentinel IT solutions capability, and increasing sales and marketing programs, headcount, and capabilities. As we've been saying for some time, with better reimbursement of superficial radiation therapy for non-melanoma skin cancer and lower reimbursement for Mohs surgery, along with data suggesting that one in five Americans will develop skin cancer, we have powerful tailwinds to support our programs. Recall that in January 21, our SRT therapy received improved reimbursement from the Centers for Medicare and Medicaid Services when they revalued our main code upwards by 66% for a course of SRT in non-melanoma skin cancer. In addition, ancillary codes received a double-digit boost We continue to capitalize on these reimbursement changes, and more and more practitioners are recognizing SRT as a best practice for the non-invasive treatment of non-melanoma skin cancer. Our rigorous physician education program highlighting the improved return on investment for SRT is ongoing, especially at dermatology conferences and trade shows. In fact, this weekend at the important South Beach Symposium in Miami, a key opinion leader, Dr. Michael Gold, will be discussing SRT and its benefits. This will be followed up two weeks later at the Winter Clinical Conference in Miami by another key opinion leader, Dr. Mark Nestor. We recently launched important upgrades to this system, including new state-of-the-art solid-state high-frequency ultrasounds. which provides the industry's best view of the epidermis and utilizes a new ergonomically designed probe with single-use disposables. This upgrade system is garnering interest among physicians, and the SRT100 Vision has become our leading SRT product. The Fair Market Value Lease Program we launched earlier last year continues to support purchases of our feature-rich SRT100 vision system and its percentage of system sales continues to increase. While we are maintaining focus on our core dermatology business and providing products our customers need and want, radiation oncology is another important avenue for growth. We're gaining awareness among radiation oncologists and recently sold an SRT100 plus system to a large luminary hospital in the Northeast. And with that overview, I'd like to turn the call over to Michael Sardano for a bit more color on the quarter.